Log In
Print
BCIQ
Print
Print this Print this
 

Arzerra, ofatumumab (HuMax-CD20)

Also known as: 2F2

  Manage Alerts
Collapse Summary General Information
Company Genmab A/S
DescriptionHuman mAb against CD20
Molecular Target CD20
Mechanism of ActionBinds CD20; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$16,000.0M

$14,500.0M

$1,500.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today